Aged Blood Accelerates Alzheimer’s, While Young Blood Shows Protective Effects, New Study Reveals
A groundbreaking new study suggests a direct link between the composition of blood and the progression of Alzheimer’s disease, offering potential new avenues for therapeutic intervention. Researchers have found that components in aged blood can accelerate the accumulation of harmful proteins in the brain, while blood from younger individuals appears to offer a protective effect.
Recent research increasingly focuses on the interplay between bodily processes and changes within the brain in the context of neurodegenerative diseases. Scientists have been evaluating substances circulating in the blood for their potential influence on disease evolution, and mounting evidence suggests these circulating factors play a significant role.
The study, published in the journal Aging, utilized an experimental model of Alzheimer’s disease in mice. Over a period of 30 weeks, mice received weekly infusions of blood from either young or aged animals. The goal was to determine whether these circulating substances could impact the buildup of amyloid plaques – a hallmark of Alzheimer’s – and associated behavioral changes.
Alzheimer’s disease, the leading cause of dementia globally, is characterized by the accumulation of beta-amyloid protein (βA) in the brain. These proteins form plaques that disrupt communication between nerve cells and contribute to neurodegeneration. While beta-amyloid is primarily produced in the central nervous system, its presence in the blood has prompted investigation into a potential connection between systemic factors and the disease’s progression.
Researchers employed Tg2576 transgenic mice, a commonly used model in Alzheimer’s research, to test the role of age-related blood factors. Donors were categorized as young (50–75 days old) or aged (443–532 days old), and their blood was transfused into 120-day-old Tg2576 mice. These recipient mice were then assessed for spatial memory and underwent postmortem brain tissue analysis.
The results were striking. Aged blood appeared to accelerate the accumulation of amyloid proteins and negatively impact behavior, while young blood demonstrated protective qualities. Cognitive performance was evaluated using the Barnes test, a behavioral assessment of spatial memory in rodents. Histological and biochemical techniques measured amyloid plaque accumulation, and proteomic analysis – a large-scale study of proteins – was conducted on the treated brains.
This proteomic analysis identified over 250 proteins with altered expression, particularly those associated with synaptic functions, endocannabinoid signaling, and calcium channels. These changes, researchers believe, could explain the observed behavioral and pathological differences.
“This research reinforces the importance of understanding how systemic factors condition the brain environment and directly influence the mechanisms that promote disease progression,” explained Dr. Claudia Durán-Aniotz, from BrainLat, Universidad Adolfo Ibanez. “By demonstrating that peripheral signals derived from aged blood can influence central processes in the pathophysiology of Alzheimer’s disease, these results open new opportunities to study therapeutic targets oriented to the blood-brain axis.”
The large-scale proteomic analysis was performed by the MELISA Institute, utilizing state-of-the-art equipment to generate high-quality data from complex plasma samples. The researchers emphasize the solid scientific foundation of their findings.
The study’s authors conclude that circulating blood factors can directly influence the progression of neurodegenerative diseases like Alzheimer’s. Understanding these mechanisms could lead to the identification of novel therapeutic targets and preventative strategies. The team’s next step is to pinpoint the exact nature of these factors and evaluate potential interventions in human trials.
The research was a collaborative effort involving scientists from the Instituto Latinoamericano de Salud Cerebral (BrainLat) at Universidad Adolfo Ibáñez, along with collaborators from the MELISA Institute, the University of Texas Health Science Center at Houston, and the Universidad Mayor.
Keep reading
